Chime Biologics Limited Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2013

Location

Wuhan Hubei Province China

Primary Industry

Biotechnology

About

Based in Wuhan, China, and founded in 2013, Chime Biologics Limited provides biopharmaceutical development and manufacturing solutions. In 2021, the company raised funding from Fidelity International, Panacea Venture, and VMS Group. The company employs over 400 people. Chime Biologics Limited offers integrated solutions for early-stage drug development to late-stage clinical research and commercial cGMP (current good manufacturing) production. The company’s integrated platform offers cell Line development, process development, process transfer, quality control and assurance (QC/QA), protein science characterization, clinical manufacturing (DS/DP), commercial manufacturing (DS/DP), material management & logistics, and regulatory support. Chime Biologics also provides biologics manufacturing capability for monoclonal antibodies, bispecific antibodies, fusion proteins, conjugated proteins, and enzymes.

Current Investors

Fidelity International, VMS Group, Panacea Venture

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals

Website

www.chimebiologics.com

Verticals

Manufacturing

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.